Asymmetric dimethylarginine (ADMA) activates nuclear factor (NF)-kB in endothelial cells, while actin-stabilizing or -destabilizing drugs prevent ADMA-induced activation of NF-kB. Here we investigated how actin-targeting drugs regulated ADMA-induced NF-kB activation in endothelial cells. Human umbilical vein endothelial cells were treated with ADMA for 24 h in the absence and presence of cytochalasin D or jasplakinolide. Expression levels of proteins and genes were measured by immunoblotting and reversetranscription polymerase chain reaction, respectively. Chromatin immunoprecipitation was used to detect the binding of NF-kB to the vascular cell adhesion molecule 1 (VCAM-1) promoter. The association of actin with RelA/ P65 was detected by immunoprecipitation. It was demonstrated that ADMA induced IkBa degradation, increased nuclear RelA/P65 translocation, and promoted the binding of NF-kB to the VCAM-1 promoter. Consequently, this increased the expression of VCAM-1. In parallel studies, actin-stabilizing and -destabilizing drugs decreased ADMAinduced RelA/P65 nuclear translocation, interfered with NF-kB binding to the VCAM-1 promoter and prevented the expression of VCAM-1. This was independent of total RelA/ P65 levels and ADMA-induced IkBa degradation. Most importantly, the association of RelA/P65 with actin was increased after stimulation with ADMA, and impaired after treatment with actin-targeting drugs. In brief, actinstabilizing or -destabilizing drugs interfere with the ADMAinduced association of RelA/P65 with actin, and consequently disrupt NF-kB activation.
Introduction
Asymmetric dimethylarginine (ADMA) is a residue of proteolysis of arginine-methylated proteins, and is a competitive inhibitor of nitric oxide synthase (NOS) enzymes. In recent years, it has been reported that ADMA is a risk marker for various diseases, such as chronic kidney disease [1] , stable coronary artery disease [2] , chronic heart failure [3] , peripheral arterial disease [4] , and type 2 diabetes mellitus [5] . The main pathological actions of ADMA, such as the triggering endothelial inflammation, occur in the endothelium. A previous study demonstrated that NF-kB might play a pivotal role in ADMA-induced endothelial inflammation [6] .
NF-kB is a heterodimeric protein, with 50 (P50) and 65 kDa (P65) subunits, and is bound in the cytoplasm to a retention protein IkB. This keeps NF-kB inactive in the cytosol by masking its nuclear localization signal (NLS) [7] . IkB rapidly disappears following treatment with NF-kB inducers that unmask the NLS. This allows NF-kB to be transported to the nucleus and activate transcription of target genes, such as vascular cell adhesion molecule 1 (VCAM-1). VCAM-1 selectively promotes binding of mononuclear leukocytes to the vascular endothelium and plays important roles in the firm attachment and transendothelial migration of leukocytes.
Inhibition of the NF-kB pathway is a potential therapy in the treatment of inflammation. Several studies have suggested that a variety of agents that stabilize or destabilize the actin cytoskeleton are capable of inhibiting NF-kB [8, 9] . Actin filaments can be either stable, with their lengths precisely specified, or dynamic, undergoing rapid polymer elongation and shrinkage. Dynamic actin networks play a critical role in a variety of cellular processes including cellular motility and signal transduction. Recent study from our lab has shown that disturbing the dynamics of actin filaments with drugs resulted in prevention of ADMA-induced NF-kB activation [10] . However, the mechanism(s) of how these drugs blocked ADMA-induced NF-kB activation is not well understood.
In this study, we attempted to demonstrate that actin-stabilizing or -destabilizing drugs disrupted the ADMA-induced association of RelA/P65 with actin, thereby impairing nuclear transport of RelA/P65. We also showed that these drugs interfered with NF-kB binding to the VCAM-1 promoter, preventing the expression of VCAM-1. 
Materials and Methods

Materials
Cell culture
HUVECs were cultured in gelatin-coated flasks using endothelial cell medium (Sciencell Inc.) with bullet kit additives (Sciencell Inc.) and 5% fetal bovine serum (FBS; Sciencell Inc.) [11] . HUVECs between passages 3 and 6 were used.
Drug treatments
HUVECs at 60%-70% confluency were pretreated with 5 mM Cyt D, an actin-destabilizing drug, or 1 mM Jas, an actin-stabilizing drug for 30 min. Then 100 mM of ADMA was added and the cells were incubated for 24 h.
Extraction of cytoplasmic and nuclear contents
After treatments, cells were washed twice with ice-cold Tris-buffered saline, and resuspended in 400 ml of buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride). After 15 min, Nonidet P-40 was added to a final concentration of 0.6% (v/v). Samples were centrifuged and supernatants containing cytosolic proteins were collected. Pelleted nuclei were resuspended in 50 ml of buffer B (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride). After 30 min at 48C, lysates were centrifuged and supernatants containing nuclear proteins were transferred to new vials.
Cell lysis
Cells were harvested in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25 mM EDTA, pH 8.0, 1% deoxycholic acid, 1% Triton X-100, 5 mM NaF, and 1 mM sodium orthovanadate) supplemented with protease inhibitors.
Immunoprecipitation and immunoblotting
Cell lysates were immunoprecipitated with the indicated antibodies as described previously [12] . For immunoblotting, 20 mg of protein samples were subject to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes (Amersham International plc, Cardiff, UK). Membranes were incubated in 5% (w/v) skimmed milk in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, and 0.1% Tween-20) with shaking for 2.5 h at room temperature to block residual binding sites. This was followed by an overnight incubation with the appropriate primary antibody at 48C, then a secondary antibody at room temperature for 1 h with shaking. Membranes were processed using an enhanced chemiluminescence kit (Millipore, Billerica, USA) and exposed to Kodak X-OMAT film (Eastman Kodak Co., Rochester, USA). The primary antibodies used in this study were as followed: anti-RelA/P65 ( Quantitative polymerase chain reaction assays Total RNA was isolated from HUVECs using Trizol (Invitrogen, Carlsbad, USA) and reverse transcribed into cDNA with a reverse transcription system (Promega, Madison, USA) according to the manufacturer's instructions. The quantitative polymerase chain reaction (qPCR) assays were conducted on a 7300 Real-time PCR system (Applied Biosystems, Foster City, USA) with Power SYBR green PCR master mix (Applied Biosystems) according to the manufacturer's instructions. The expression level of VCAM-1 mRNA was quantified and normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). All reactions were performed in triplicate with samples derived from three independent experiments. The following primer pairs were used in the qPCR assays: VCAM-1 forward 
Chromatin immunoprecipitation assays
To detect the association of nuclear proteins with the VCAM-1 promoter, chromatin immunoprecipitation (ChIP) analysis was conducted as previously described [13] with some modifications. After drug treatment, cell lysates were immunoprecipitated with an antibody against RelA/P65. Immunoprecipitated DNA samples were extracted with phenol-chloroform, and the purified DNA pellet was resuspended in H 2 O and subjected to PCR with forward primer 5 0 -AAATCAATTCACATGGCATA-3 0 and reverse primer 5 0 -AAGGGTCTTGTTGCAGAGG-3 0 specific for the VCAM-1 promoter. Products were electrophoresed and visualized on 2% (w/v) agarose gels.
Disruption of the association between RelA/p6 and actin Statistical analysis Data were expressed as the mean + standard error (SE). Comparisons between experimental groups were made using one-way analysis of variance tests. Differences in mean values were considered significant when the P value was less than 0.05.
Results
Actin-targeting drugs prevent ADMA-induced RelA/ P65 nuclear accumulation and VCAM-1 expression Actin-stabilizing or -destabilizing drugs interfered with ADMA-induced nuclear translocation of RelA/P65 as determined by immunofluorescence [10] . It was further confirmed by the western blotting results. Cyt D and Jas were used, respectively, to destabilize or stabilize actin filaments [8] . Analysis of nuclear extracts by western blotting analysis showed that ADMA (100 mM) increased the nuclear RelA/ P65 level ( Fig. 1) , indicating that nuclear translocation of RelA/P65 was elevated. Cyt D or Jas interfered with ADMA-induced nuclear translocation of RelA/P65. These findings corresponded with our previous immunofluorescence results [10] . Besides, ADMA increased the VCAM-1 RNA and protein expression levels as expected. Cyt D and Jas suppressed ADMA-driven VCAM-1 expression (Fig. 2) .
Effects of actin-targeting drugs on ADMA-induced NF-kB binding to the VCAM-1 promoter ChIP assay results confirmed that actin-targeting drugs repressed VCAM-1 expression by down-regulating NF-kB binding to the promoter. We found that RelA/P65 binding to the VCAM-1 promoter was increased during ADMA stimulation. The recruitment of RelA/P65 to the VCAM-1 promoter was repressed by treatment with Cyt D or Jas (Fig. 3) .
Actin-targeting drugs have no effect on ADMA-mediated degradation of IkBa IkB interaction with NF-kB has two consequences: retention of NF-kB in the cytoplasm and inhibition of DNA binding to NF-kB. Therefore, the degradation of IkB is a prerequisite for NF-kB activation. We measured the cytoplasmic IkBa levels to determine whether actin-targeting drugs disturbed ADMA-induced IkBa degradation. ADMA (100 mM, 24 h) induced remarkable degradation of IkBa. However, Jas (1 mM) or Cyt D (5 mM) failed to block ADMA-induced IkBa degradation (Fig. 4) .
ADMA does not influence RelA/P65 levels and actin-targeting drugs fail to induce degradation of RelA/P65 It is reported that ubiquitination of RelA/P65 leads to its degradation and impairment of RelA/P65 nuclear translocation [14, 15] . But there were no significant changes observed in total RelA/P65 levels following treatment with Cyt D or Jas, regardless of ADMA challenge (Fig. 5) .
Actin-targeting drugs inhibit ADMA-induced association of RelA/P65 with actin The association of RelA/P65 with actin may facilitate the RelA/P65 nuclear translocation [16] . Immunoprecipitates of actin from control and ADMA-challenged cells were analyzed to determine the association of actin with RelA/P65 in endothelial cells. ADMA (100 mM) induced a strong interaction of actin with RelA/P65. We did not detect RelA/P65 or actin in the immunoprecipitates from IgG controls, indicating the specificity of the interaction. Pretreatment of cells with Cyt D (5 mM) or Jas (1 mM) prevented ADMA-induced association of actin with RelA/P65 (Fig. 6) . Disruption of the association between RelA/p65 and actin
Discussion
Previous studies have suggested that ADMA, in addition to inhibiting NOS, may also participate in inflammation processes related to endothelial dysfunction [17] [18] [19] .
The NF-kB signaling pathway may be involved in the inflammatory reaction induced by ADMA [20] . Our recent results showed that ADMA promoted nuclear DNA binding to NF-kB in HUVECs, while actin-targeting drugs interfered with nuclear NF-kB DNA-binding activity, thereby inhibiting expression of ICAM-1 [10] . We also reported previously that disturbing actin dynamics interfered with ADMA-induced NF-kB activation in glomerular endothelial cells [21] . In this work, we further investigated how actin-targeting drugs regulate ADMA-induced NF-kB activation in endothelial cells. Actin-targeting drugs can be divided into two groups depending on their effects on the actin cytoskeleton: actin-stabilizing or -destabilizing drugs. Jas is an actin filament stabilizer isolated from the marine sponge Jaspis johnstoni [22] . It is a potent inducer of actin polymerization [23] . Cyt D acts as an actin destabilizer by binding to the barbed ends of actin filaments and preventing them from further polymerization or shortening. At high concentrations, Cyt D can also sequester actin monomers and sever actin filaments [24] . Jas and Cyt D are two of the most useful actin-targeting drugs that can be used to study the role of the actin cytoskeleton on signal transduction. Jas and Cyt D were used to stabilize or destabilize the actin filaments and we demonstrated that stabilizing or Disruption of the association between RelA/p6 and actin destabilizing actin filaments inhibited ADMA-induced VACM-1 expression. VCAM-1 and ICAM-1 belong to an immunoglobulin-like family of adhesion molecules, but VCAM-1 showed a slower time course than ICAM-1, peaking at 24 h in some models [25] . VCAM-1 is associated with chronic types of inflammation, such as that observed in atherosclerosis [26] .
ChIP is a powerful method to detect the access of nuclear proteins to their target promoters in the natural chromatin environment. ChIP was used to verify that whether actintargeting drugs repressed VCAM-1 expression by downregulating NF-kB binding to the promoter. ADMA was found to induce RelA/P65 binding to the VCAM-1 promoter, while actin-targeting drugs interfered with ADMAinduced RelA/P65 binding to the VCAM-1 promoter.
It is well known that NF-kB activation is a complex process and many factors may affect the activation of NF-kB. Therefore, we explored how actin-targeting drugs inhibit NF-kB activation. NF-kB activation is tightly controlled by its natural inhibitor, IkBa. Degradation of IkBa is essential for RelA/P65 nuclear transport. Masking the NLSs of NF-kB subunits by IkBa proteins is the major mechanism of cytoplasmic retention for NF-kB. ADMA promoted strong degradation of IkBa; however, actin-stabilizing or -destabilizing drugs failed to block ADMA-induced degradation of IkBa. This result excluded the possibility that actintargeting drugs inhibited the IKK complex, IkBa ubiquitin ligase, or 26S proteasome activation [27, 28] .
Ubiquitination of RelA/P65 leads to its degradation and impairment of RelA/P65 nuclear translocation [14, 15] . To exclude this possibility, we determined total RelA/P65 levels. There were no significant changes observed in total RelA/P65 levels following treatment with Cyt D or Jas, regardless of whether an ADMA challenge was issued. We postulated that there was impairment in the progress of the released NF-kB dimer transporting into the nucleus after treatment with Cyt D or Jas.
It has been reported that the association of RelA/P65 with actin may facilitate RelA/P65 nuclear translocation [16] . We believe that ADMA might promote the association of RelA/P65 with actin, and attempted to determine Bar graphs represent the effects of Cyt D or Jas on ADMA-induced IkBa degradation. IkBa levels were normalized to actin and expressed relative to the untreated control, which was set at 1. Data are shown as the mean + SE (n ¼ 3 for each condition). *P , 0.05 vs. controls. Not significant (NS), P . 0.05. Figure 5 Effects of Cyt D or Jas on total RelA/P65 levels in the absence or presence of ADMA Bar graph represents the effects of Cyt D or Jas on the total levels of RelA/P65 in the absence or presence of ADMA. RelA/P65 levels were normalized to actin and expressed relative to the untreated control, which was set at 1. Data are expressed and shown as the mean + SE (n ¼ 3 for each condition). Not significant (NS), P . 0.05.
Disruption of the association between RelA/p65 and actin whether this association could be disrupted by actintargeting drugs. Our findings showed that ADMA induced a specific association of RelA/P65 with actin. However, actin-targeting drugs abolished this association. Therefore, interference in the RelA/P65 and actin association might be the main mechanism by which actin-targeting drugs disrupt ADMA-induced NF-kB activation in endothelial cells. We also analyzed the association of RelA/P65 and actin in nuclear extracts. In contrast to our expectations, we failed to detect any existence of this association in the nucleus (data not shown). Therefore, we conclude that RelA/P65 is associated with actin mainly in the cytoplasm.
Other researchers have reported similar results, where actin-targeting drugs inhibit thrombin-induced association of RelA/P65 with actin and subsequent NF-kB activation in endothelial cells. At the same time, actin-targeting drugs had no effect on tumor necrosis factor-a-induced NF-kB activation. This indicates that these drugs act along a stimulatordependent pathway [16] . Thrombin is a serine protease that activates platelets, leukocytes, endothelial cells, and mesenchymal cells at sites of vascular injury. ADMA is a residue of the proteolysis of arginine methylated proteins; it promotes platelet aggregation and adhesion of monocytes. The mechanistic similarity between thrombin-and ADMA-induced activation is intriguing but requires further investigation.
There were a number of limitations associated with our study. The concentrations of ADMA used in this study were similar to those previously reported [21, 29] , and were much higher than those in the plasma of patients. For the in vitro experiments, the duration was limited; therefore, a low dose of ADMA (5 mM), similar to that observed in uremia patients, failed to activate the NF-kB (data not shown). The effects of low doses of ADMA in conjunction with long-term stimulation upon NF-kB activation need to be further studied in vivo. Although Cyt D and Jas are widely used as tools to study the function of the actin cytoskeleton in cells and animals, they are not suitable as pharmacological treatments because of their poor uptake into cells or specific adverse side effects. Therefore, less toxic but effective actin-targeting drugs need to be found.
From our findings, we have provided evidence that ADMA induced an association between RelA/P65 and actin, and that it might be important for the inflammatory process. Specific drugs that disrupt the association of RelA/P65 with actin may be useful in preventing ADMA-activated inflammatory responses and endothelial dysfunction. Figure 6 Actin-targeting drugs prevented ADMA-induced association of actin with RelA/P65 RelA/P65-actin association is expressed as a fold increase relative to the untreated control. Data are shown as the mean + SE (n ¼ 3 for each condition). *P , 0.05 vs. controls. #P , 0.05 vs. ADMA-stimulated controls. TL, total lysate.
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